B. Riley Issues Negative Forecast for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Research analysts at B. Riley lowered their Q1 2025 EPS estimates for shares of Harrow in a report released on Monday, March 31st. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.01) for the quarter, down from their previous estimate of $0.15. B. Riley currently has a "Buy" rating and a $65.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million.

Separately, HC Wainwright restated a "buy" rating and set a $57.00 target price on shares of Harrow in a research report on Monday, March 31st.

Harrow Trading Up 0.2 %

NASDAQ HROW traded up $0.04 on Thursday, reaching $23.13. The company had a trading volume of 235,879 shares, compared to its average volume of 471,556. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The stock's 50 day moving average is $27.79 and its 200-day moving average is $37.13. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a market cap of $824.68 million, a price-to-earnings ratio of -24.55 and a beta of 0.46.

Institutional Trading of Harrow

Several hedge funds have recently added to or reduced their stakes in the business. Braidwell LP increased its holdings in shares of Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after acquiring an additional 467,401 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after purchasing an additional 194,480 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock worth $11,313,000 after purchasing an additional 166,602 shares in the last quarter. Two Sigma Investments LP raised its holdings in Harrow by 483.2% during the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company's stock worth $5,044,000 after buying an additional 124,574 shares during the period. Finally, Neuberger Berman Group LLC raised its holdings in Harrow by 128.0% during the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company's stock worth $6,728,000 after buying an additional 112,588 shares during the period. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.